Tamoxifen
(Synonyms: 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen) 目录号 : GC17901
Tamoxifen(他莫西芬)是一种选择性雌激素受体调节剂 (SERM),可阻断乳腺细胞中的雌激素作用,并可激活不同组织细胞中的雌激素活性;Tamoxifen 还可以作为 Hsp90 激活剂,增强 Hsp90 分子伴侣 ATPase 的活性;Tamoxifen 还可以诱导 CreER(T2) 小鼠的基因敲除。
Cas No.:10540-29-1
Sample solution is provided at 25 µL, 10mM.
Tamoxifen(TAM) serves as a selective estrogen receptor regulator (SERM), inhibiting estrogen's effects in breast cells while potentially stimulating estrogen activity in cells found in different tissues. Moreover, Tamoxifen can function as an enhancer of Hsp90 chaperone ATPase activity. Furthermore, it has been shown to induce gene knockout in CreER(T2) mice[1-4].
Tamoxifen(1-10µM;24 h) treatment significantly reduced the levels of growth hormone (GH) and adrenocorticotropic hormone (ACTH) secreted by the GH3 and AtT-20 cells respectively[5]. Tamoxifen(0.1-100 µM;48h) decreased the mRNA expression of vascular endothelial growth factor-A (VEGF-A) and increased the mRNA expression of VEGF receptor-1 and placental growth factor (PLGF) in HEECs[6]. Tamoxifen Treatment(1µM; 24/48/96 h) can significantly inhibit the proliferation of MCF7 cells[7]. 5 µM Tamoxifen induces persistent ERK1/2 activation in ER+ breast cancer cells(MCF-7)[8].
Tamoxifen (20, 50 and 100 mg/kg;21 days) treatment not only led to a significant reduction in tumor volume and weight, but also decreased the plasma levels of GH in the tumor-bearing mice[5]. Mice were injected with Tamoxifen (75 mg/kg dissolved in corn oil for 5 days at 6 weeks of age；i.p.) causes floxed exon excision, resulting in gene knockout[9]. Tamoxifen(9 mg/kg；i.g.) exerts an inhibitory effect on the heterotopic bone progression at inflammation and chondrogenesis stages, with the TGF-ß signaling pathway suppressed following the increase in estrogen receptor alpha activity[10].
References:
[1]. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med. 1998 Nov 26;339(22):1609-18. doi: 10.1056/NEJM199811263392207. PMID: 9828250.
[2]. Hawariah A, Stanslas J. In vitro response of human breast cancer cell lines to the growth-inhibitory effects of styrylpyrone derivative (SPD) and assessment of its antiestrogenicity. Anticancer Res. 1998 Nov-Dec;18(6A):4383-6. PMID: 9891496.
[3].Zhao R, Leung E, et,al. Tamoxifen enhances the Hsp90 molecular chaperone ATPase activity. PLoS One. 2010 Apr 1;5(4):e9934. doi: 10.1371/journal.pone.0009934. PMID: 20376192; PMCID: PMC2848575.
[4]. Feil S, Valtcheva N, et,al. Inducible Cre mice. Methods Mol Biol. 2009;530:343-63. doi: 10.1007/978-1-59745-471-1_18. PMID: 19266339.
[5]. Lv T, Zhang Z, et,al. Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration. Int J Mol Sci. 2022 Feb 28;23(5):2664. doi: 10.3390/ijms23052664. PMID: 35269804; PMCID: PMC8910631.
[6]. Helmestam M, Andersson H, et,al. Tamoxifen modulates cell migration and expression of angiogenesis-related genes in human endometrial endothelial cells. Am J Pathol. 2012 Jun;180(6):2527-35. doi: 10.1016/j.ajpath.2012.02.026. Epub 2012 Apr 21. PMID: 22531128.
[7]. RondÓn-Lagos M, Rangel N, et,al. Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes. Endocr Relat Cancer. 2016 Aug;23(8):635-50. doi: 10.1530/ERC-16-0078. Epub 2016 Jun 29. PMID: 27357940; PMCID: PMC5064758.
[8]. Zheng A, Kallio A, et,al. Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen. Endocrinology. 2007 Jun;148(6):2764-77. doi: 10.1210/en.2006-1269. Epub 2007 Mar 15. Erratum in: Endocrinology. 2007 Aug;148(8):3931. PMID: 17363451.
[9]. Kedjouar B, de MÉdina P, et,al. Molecular characterization of the microsomal tamoxifen binding site. J Biol Chem. 2004 Aug 6;279(32):34048-61. doi: 10.1074/jbc.M405230200. Epub 2004 Jun 2. PMID: 15175332.
[10]. Mao D, Mi J, et,al. Tamoxifen Inhibits the Progression of Trauma-Induced Heterotopic Ossification in Mice. Med Sci Monit. 2019 Oct 21;25:7872-7881. doi: 10.12659/MSM.916733. PMID: 31631887; PMCID: PMC6820362.
Tamoxifen(他莫西芬)是一种选择性雌激素受体调节剂 (SERM),可阻断乳腺细胞中的雌激素作用,并可激活不同组织细胞中的雌激素活性;Tamoxifen 还可以作为 Hsp90 激活剂,增强 Hsp90 分子伴侣 ATPase 的活性;Tamoxifen 还可以诱导 CreER(T2) 小鼠的基因敲除[1-4]。
Tamoxifen (1-10µM;24 h)处理显著降低了GH3和AtT-20细胞分泌的生长激素和肾上腺皮质激素的水平[5]。Tamoxifen(0.1-100 µM;48h)降低了HEECs细胞中血管内皮生长因子-A的mRNA表达水平,并增加了VEGF-1受体和胎盘生长因子的mRNA表达水平[6]。Tamoxifen处理(1µM; 24/48/96 h)可以显著抑制MCF7细胞的增殖[7]。5 µM的Tamoxifen在ER+乳腺癌细胞(MCF-7细胞)中诱导持续的ERK1/2活化[8]。
Tamoxifen (20, 50 and 100 mg/kg;21 days)治疗不仅显著减少了肿瘤体积和重量,还降低了肿瘤负荷的小鼠血浆中GH水平[5]。小鼠在6周龄时注射Tamoxifen (75 mg/kg dissolved in corn oil for 5 days at 6 weeks of age；i.p.),导致外显子切除,基因敲除[9]。Tamoxifen (9mg /kg; ig)在炎症和软骨形成阶段对异位骨进展有抑制作用,随着雌激素受体α活性的增加,TGF-ß信号通路受到抑制[10]。
| Cell experiment [1]: | |
|
Cell lines |
GH3 and AtT-20 cells |
|
Preparation Method |
GH3 and AtT-20 cells were cultured with different concentrations of Tamoxifen for 24 h. |
|
Reaction Conditions |
1-10µM;24 h |
|
Applications |
Tamoxifen treatment significantly reduced the levels of growth hormone (GH) and adrenocorticotropic hormone (ACTH) secreted by the GH3 and AtT-20 cells respectively. |
| Animal experiment [2]: | |
|
Animal models |
Seven to eight-week-old female BALB/c-nu nude mice(bearing GH3 cells) |
|
Preparation Method |
The mice were treated with 20, 50 and 100 mg/kg Tamoxifen every day for 21 days. |
|
Dosage form |
20, 50 and 100 mg/kg;21 days |
|
Applications |
Tamoxifen treatment not only led to a significant reduction in tumor volume and weight, but also decreased the plasma levels of GH in the tumor-bearing mice. |
|
References: [1]. Lv T, Zhang Z, et,al. Tamoxifen Exerts Anticancer Effects on Pituitary Adenoma Progression via Inducing Cell Apoptosis and Inhibiting Cell Migration. Int J Mol Sci. 2022 Feb 28;23(5):2664. doi: 10.3390/ijms23052664. PMID: 35269804; PMCID: PMC8910631. |
|
| Cas No. | 10540-29-1 | SDF | |
| 别名 | 他莫昔芬; ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen | ||
| 化学名 | 2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-ethanamine | ||
| Canonical SMILES | CC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)\C3=CC=CC=C3 | ||
| 分子式 | C26H29NO | 分子量 | 371.51 |
| 溶解度 | ≥ 18.6mg/mL in DMSO; ≥ 40 mg/mL in Ethanol | 储存条件 | 4°C, protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.6917 mL | 13.4586 mL | 26.9172 mL |
| 5 mM | 0.5383 mL | 2.6917 mL | 5.3834 mL |
| 10 mM | 0.2692 mL | 1.3459 mL | 2.6917 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet